Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Marion Gruber, director of the agency’s Office of Vaccines Research & Review is leaving at the end of October. Phil Krause, OVRR’s deputy director, is exiting in November.
This is an effort to eliminate severe adverse reactions by matching the birth control to the genetics and hormones of the individual.
As CEO, Stolpe has presided over some highs with the launch of JAK1 inhibitor Jyseleca (filgotinib) in Europe, as well as the devaluation of the company’s share price by 70%.
Teva announced the appointment in a filing with the U.S. Securities and Exchange Commission. Zaks will serve on the board’s Science and Technology Committee.
AC Immune and Genentech announced that their Phase II Lauriet trial of semorinemab in mild-to-moderate Alzheimer’s disease hit one of its co-primary endpoints.
While the speed of science is both lauded and mistrusted by near-equal parts of the population, the over 22 million Americans with cancer are now saying, “Wait, what about us?”
Newly launched Versanis Bio is aiming to turn a Novartis drug that was once developed to help with muscle loss and weakness into an anti-obesity treatment.
Today, activists with the AIDS Healthcare Foundation are setting up to protest in front of Moderna’s Cambridge headquarters.
Johnson & Johnson announced failed Imbokodo Phase IIb trial in HIV. The study evaluated the company’s investigational HIV vaccine regimen in young women in sub-Saharan Africa.
The trial will enroll about 4,000 people worldwide to confirm the drug’s safety and immunogenicity profiles.
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
The burgeoning genetic capabilities were instrumental in causing Semigran to transition into the biotech industry.